GPRC6A and Familial prostate cancer: Finally, we found that GPRC6A mediates prostate cancer progression in vivo by assessing the response to osteocalcin in human prostate cancer xenograft models of cells expressing endogenous GPRC6A or with CRISPR/Cas9 mediated deletion of GPRC6A.